Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of DWP16001 in T2D Patients with Renal Impairment
NCT04221399Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-time Curve and 2 more. Status: unknown.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04221399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221399.